Table 2. Characteristics of retrospective cohort, by persistence of elevated serum TBA.
| Characteristics | None-low persistence of elevated TBA (n = 1773), number (%) or median (interquartile range) | Medium persistence of elevated TBA (n = 267), number (%) or median (interquartile range) | P value, medium versus none-low | High persistence of elevated TBA (n = 222), number (%) or median (interquartile range) | P value, high versus none-low |
|---|---|---|---|---|---|
| Loss to follow-up | 462 (26.1) | 83 (31.1) | 0.08 | 68 (30.6) | 0.15 |
| Follow-up, y | 6.4 (5.3–7.6) | 6.0 (5.1–7.3) | 0.001 | 6.0 (4.9–7.1) | 0.001 |
| Age at entry, y | |||||
| <30 | 586 (33.0) | 78 (29.2) | 28 (12.6) | ||
| 30–39 | 759 (42.8) | 94 (35.2) | 88 (39.6) | ||
| 40–49 | 294 (16.6) | 73 (27.3) | 0.001 | 66 (29.7) | <0.001 |
| ≧50 | 134 (7.6) | 22 (8.2) | 40 (18.0) | ||
| Sex | |||||
| Female | 452 (25.5) | 55 (20.6) | 45 (20.3) | ||
| Male | 1321 (74.5) | 212 (79.4) | 0.08 | 177 (79.7) | 0.09 |
| Cirrhosis | |||||
| Non-cirrhosis | 1027 (57.9) | 109 (40.8) | 44 (19.8) | ||
| Cirrhosis without ascites | 702 (39.6) | 123 (46.1) | <0.001 | 112 (50.4) | <0.001 |
| Cirrhosis with ascites | 44 (2.5) | 35 (13.1) | 66 (29.7) | ||
| APRI at the end | |||||
| <0.5 | 965 (61.5) | 99 (40.9) | 47 (22.7) | ||
| 0.5–1.5 | 539 (34.4) | 115 (47.5) | <0.001 | 78 (37.7) | <0.001 |
| >1.5 | 64 (4.1) | 28 (11.6) | 82 (39.6) | ||
| Persistence of elevated ALT | |||||
| None-low | 1166 (65.8) | 145 (54.3) | 124 (55.9) | ||
| Medium | 440 (24.8) | 86 (32.2) | 0.001 | 63 (28.4) | 0.003 |
| High | 167 (9.4) | 36 (13.5) | 35 (15.8) | ||
| Persistence of elevated HBV DNA | |||||
| None-low | 1419 (80.0) | 208 (77.9) | 180 (81.1) | ||
| Medium | 242 (13.6) | 45 (16.8) | 0.32 | 29 (13.1) | 0.93 |
| High | 112 (6.3) | 14 (5.2) | 13 (5.9) | ||
| Baseline HBeAg | |||||
| Serum negative | 882 (49.8) | 140 (52.4) | 133 (59.9) | ||
| Serum positive | 891 (50.2) | 127 (47.6) | 0.41 | 89 (40.1) | 0.004 |